Motoi Hosoe

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2020 · 150 citations · Full text

Asthma, Allergy, Twice-daily Fluticasone–salmeterol +7

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study

Masaharu Kinoshita, Sang Haak Lee, Liang‐Wen Hang et al. · Respirology · 2011 · 41 citations

24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol

Naruhiko Sugihara, Shigeto Kanada, Michiko Haida et al. · Respiratory Medicine · 2010 · 21 citations

Asthma, Pulmonary Care, Allergy +9

Efficacy, Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease

Motoi Hosoe, Ralph Woessner, Soichiro Matsushima et al. · Clinical Drug Investigation · 2010 · 15 citations

Thrombosis, Antifibrotic Therapy, Advanced Lung Disease +7

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma

Roland Buhl, Ana-Maria Tanase, Motoi Hosoe et al. · Pulmonary Pharmacology & Therapeutics · 2020 · 15 citations · Full text